Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines.

ABSTRACT: Nipah virus (NiV) and Hendra virus (HeV) are closely related, recently emerged paramyxoviruses that are capable of causing considerable morbidity and mortality in several mammalian species, including humans. Henipavirus-specific vaccines are still commercially unavailable, and development of novel antiviral strategies to prevent lethal infections due to henipaviruses is highly desirable. Here we describe the development of adeno-associated virus (AAV) vaccines expressing the NiV G protein. Characterization of these vaccines in mice demonstrated that a single intramuscular AAV injection was sufficient to induce a potent and long-lasting antibody response. Translational studies in hamsters further demonstrated that all vaccinated animals were protected against lethal challenge with NiV. In a

SUBMITTER: Ploquin A 

PROVIDER: S-EPMC7107322 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature